Severe Acute Respiratory Syndrome Coronavirus 2 Human Challenge Trials: Too Risky, Too Soon

Journal of Infectious Diseases 222 (3):514-516 (2020)
Download Edit this record How to cite View on PhilPapers
Abstract
Eyal et al have recently argued that researchers should consider conducting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) human challenge studies to hasten vaccine development. We have conducted (J. L.) and overseen (L. D.) human challenge studies and agree that they can be useful in developing anti-infective agents. We also agree that adults can autonomously choose to undergo risks with no prospect of direct benefit to themselves. However, we disagree that SARS-CoV-2 challenge studies are ethically appropriate at this time, for 3 reasons: (1) current scientific knowledge of SARS-CoV-2 infection is insufficient to manage risks; (2) autonomous decision making, while necessary, does not override concerns about risk; and (3) undertaking challenge studies now would imperil confidence in the research enterprise, potentially undermining the global response to the coronavirus disease 2019 (COVID-19) pandemic.
Keywords
No keywords specified (fix it)
PhilPapers/Archive ID
DAWSAR
Upload history
Archival date: 2020-12-06
View other versions
Added to PP index
2020-12-06

Total views
93 ( #43,063 of 2,433,580 )

Recent downloads (6 months)
69 ( #9,996 of 2,433,580 )

How can I increase my downloads?

Downloads since first upload
This graph includes both downloads from PhilArchive and clicks on external links on PhilPapers.